Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
Q32 Bio’s Collaboration and Option Agreement with Horizon Therapeutics Ireland DAC
Scholar Rock Holding Corporation’s $205 Million Shares Offering
Goodwin Procter advised Scholar Rock Holding Corporation on the deal. Scholar Rock Holding Corporation announced the completion of its registered direct offering of 16,326,530 shares of common...
HIBio’s License Agreements with MorphoSys AG
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
Flagship Pioneering’s Collaboration Agreement with Novo Nordisk A/S
Goodwin Procter advised Flagship Pioneering on the deal. Flagship Pioneering announced its collaboration agreement with Novo Nordisk A/S to create a portfolio of novel research programs...
Tango Therapeutics’ $353 Million Merger with BCTG Acquisition Corp.
Goodwin Procter LLP advised Tango Therapeutics on the deal while Wilson Sonsini Goodrich & Rosati represented BCTG Acquisition Corp. Tango Therapeutics announced its definitive merger agreement with...
LumiraDx Limited’s Merger Agreement with CA Healthcare Acquisition
Goodwin Procter, Fried Frank and Appleby advised LumiraDx Limited on the deal, while Sidley Austin LLP acted for CA Healthcare Acquisition Corp. LumiraDx Limited announced its...
Alpha Healthcare Acquisition Corp.’s $ 1.1 Billion Business Combination With Humacyte, Inc.
Goodwin Procter LLP advised Alpha Healthcare Acquisition Corp. on the deal. Covington & Burling LLP advised Humacyte, Inc. on the deal.Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC)...